Skip to main content

Johnson & Johnson statistics

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $686.1B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Johnson & Johnson is valued at $686.1B on its latest close. Its price is 42.6 times its earnings.

Market value$686.1B
Enterprise value$715.3B
Price / earnings42.63
Price / sales6.91
Price / book8.42
EV / EBITDA21.79
EV / sales7.20
Price / free cash flow33.32
Price / free cash flow, own 5-year average23.59
EV / EBIT28.84
EV / free cash flow34.65
Free cash flow yield3.0%
Dividend yield1.9%

Share price

Latest close$285.75
Day's change+0.8%
52-week high$288.11
52-week low$193.45
From 52-week high−0.8%
Return · 1 month+11.8%
Return · 3 months+6.9%
Return · year to date+38.1%
Return · 1 year+47.0%
Beta · 1 year against the S&P 500−0.08
50-day average$266.86
200-day average$249.79
RSI 1465.6
Average volume · 20 sessions7.5M

Margins and returns

For fiscal 2025, as filed.

Gross margin67.9%
Operating margin26.8%
Net margin28.5%
Free cash flow margin20.9%
Return on equity35.0%
Return on assets11.0%
Return on invested capital14.5%
Return on invested capital, 5-year average13.9%
Return on capital employed18.4%
Stock-based compensation / revenue1.4%

Financial position

At the end of fiscal 2025.

Cash and equivalents$19.71B
Total debt$51.33B
Net debt$31.23B
Current ratio1.03
Quick ratio0.65
Debt / equity0.63
Net debt / EBITDA0.95
Interest coverage26.04

Growth

Revenue, latest quarter on a year+5.9%
Revenue, twelve months on a year+7.8%
EPS, latest quarter on a year−95.8%
EPS, twelve months on a year−36.4%
Revenue, 5-year compound+2.7%
Revenue, 10-year compound+3.0%
Net income, 5-year compound+12.8%
Free cash flow, 5-year compound−0.5%
EPS, 5-year compound+15.0%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares2.4B
Shares outstanding, 5-year compound−1.9%
Net share repurchases$5.95B
Dividends per share$5.14
Dividend payout46.2%

Taxes

For fiscal 2025, as filed.

Income tax expense$5.78B
Effective tax rate17.7%

JNJ in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.